Nuvation Bio's Chief People Officer Stacy Markel sold 125,000 shares worth $753,000 on June 23, 2026, reducing her direct holdings by 79.32%. However, the sale was executed under a pre-established trading plan adopted in December 2025, and Markel retains significant exposure through 629,810 outstanding options. Despite the stock's 190% surge over...

Robert Mashal, an oncology-trained director at Nuvation Bio, purchased 25,000 shares at $4.73 per share on June 9, 2026, bringing his total indirect holdings to 225,000 shares. The purchase comes as Nuvation's first FDA-approved cancer drug, Ibtrozi, continues gaining traction with over 200 new patients per quarter since its July 2025 launch. The...

Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio, sold 200,000 Class A shares for approximately $904,000 on April 6, 2026, reducing his direct holdings by 79%. However, he retains 53,000 shares and 700,000 stock options, suggesting the sale is a routine profit-taking exercise rather than a loss of confidence in the company. Nuvation Bio,...

The Schall Law Firm is investigating Nuvation Bio Inc. for potential securities law violations following the company's Q4 2025 earnings report. The company revealed that 75% of treatment discontinuations for its IBTROZI oncology therapy occurred in later-line patient populations, contributing to a gap between patient starts and revenue growth. Th...

Pomerantz Law Firm has filed class action lawsuits against PayPal Holdings and Snowflake Inc., with deadlines for investors to join. PayPal announced disappointing Q4 2025 earnings, CEO departure, and withdrawn 2027 guidance due to macroeconomic factors and operational issues. The firm is also investigating claims on behalf of Nuvation Bio invest...